Additional value of tau protein measurement in the diagnosis of Creutzfeldt-Jakob disease

Edina Katalin Cseh, G. Veres, Krisztina Danics, Levente Szalárdy, Nikolett Nánási, P. Klivényi, L. Vécsei, Dénes Zádori

Research output: Article

Abstract

Since the definite diagnosis of Creutzfeldt-Jakob disease (CJD) can currently only be provided by autopsy, there is a special need for fine diagnostic tools in live patients to achieve accurate diagnosis as early as possible. The aim of this study was to perform a preliminary retrospective analysis on the utility of the measurement of total Tau (tTau) and some other biomarkers from the cerebrospinal fluid (CSF) of patients with rapidly progressive dementia in the diagnostic work up of CJD. Beside the assessment of relevant clinical data and the findings of electroencephalography and brain magnetic resonance imaging, the presence of 14-3-3 protein and the levels of tTau were determined by Western blot technique and enzyme-linked immunosorbent assay from the CSF of 19 patients diagnosed with rapidly progressive dementia between the period of 2004-2017 at the Department of Neurology, University of Szeged. This preliminary study provided 100% sensitivity for 14-3-3, and interestingly, only 40% specificity to support the clinical diagnosis of CJD. Regarding tTau, the sensitivity values were calculated to be 100% or 83%, whereas the specificity values were 71% or 86%, depending on the applied cut-off levels. The poor specificity of 14-3-3 is not in line with literature data and may be the result of the small number of patients in the cohort with non-prion disease, predominantly consisting of disorders with considerable tissue damage, whereas tTau presented good sensitivity and specificity values. The combined application of these and novel chemical biomarkers may increase both sensitivity and specificity to a desired level.

Original languageEnglish
Pages (from-to)39-47
Number of pages9
JournalIdeggyogyaszati szemle
Volume72
Issue number1-2
DOIs
Publication statusPublished - jan. 30 2019

Fingerprint

tau Proteins
Creutzfeldt-Jakob Syndrome
Cerebrospinal Fluid
Dementia
Biomarkers
14-3-3 Proteins
Sensitivity and Specificity
Neurology
Electroencephalography
Autopsy
Western Blotting
Enzyme-Linked Immunosorbent Assay
Magnetic Resonance Imaging
Brain

Keywords

    ASJC Scopus subject areas

    • Neurology
    • Clinical Neurology

    Cite this

    Additional value of tau protein measurement in the diagnosis of Creutzfeldt-Jakob disease. / Cseh, Edina Katalin; Veres, G.; Danics, Krisztina; Szalárdy, Levente; Nánási, Nikolett; Klivényi, P.; Vécsei, L.; Zádori, Dénes.

    In: Ideggyogyaszati szemle, Vol. 72, No. 1-2, 30.01.2019, p. 39-47.

    Research output: Article

    Cseh, Edina Katalin ; Veres, G. ; Danics, Krisztina ; Szalárdy, Levente ; Nánási, Nikolett ; Klivényi, P. ; Vécsei, L. ; Zádori, Dénes. / Additional value of tau protein measurement in the diagnosis of Creutzfeldt-Jakob disease. In: Ideggyogyaszati szemle. 2019 ; Vol. 72, No. 1-2. pp. 39-47.
    @article{f7206fcfe7cc44569cd70c3dc0a1cba3,
    title = "Additional value of tau protein measurement in the diagnosis of Creutzfeldt-Jakob disease",
    abstract = "Since the definite diagnosis of Creutzfeldt-Jakob disease (CJD) can currently only be provided by autopsy, there is a special need for fine diagnostic tools in live patients to achieve accurate diagnosis as early as possible. The aim of this study was to perform a preliminary retrospective analysis on the utility of the measurement of total Tau (tTau) and some other biomarkers from the cerebrospinal fluid (CSF) of patients with rapidly progressive dementia in the diagnostic work up of CJD. Beside the assessment of relevant clinical data and the findings of electroencephalography and brain magnetic resonance imaging, the presence of 14-3-3 protein and the levels of tTau were determined by Western blot technique and enzyme-linked immunosorbent assay from the CSF of 19 patients diagnosed with rapidly progressive dementia between the period of 2004-2017 at the Department of Neurology, University of Szeged. This preliminary study provided 100{\%} sensitivity for 14-3-3, and interestingly, only 40{\%} specificity to support the clinical diagnosis of CJD. Regarding tTau, the sensitivity values were calculated to be 100{\%} or 83{\%}, whereas the specificity values were 71{\%} or 86{\%}, depending on the applied cut-off levels. The poor specificity of 14-3-3 is not in line with literature data and may be the result of the small number of patients in the cohort with non-prion disease, predominantly consisting of disorders with considerable tissue damage, whereas tTau presented good sensitivity and specificity values. The combined application of these and novel chemical biomarkers may increase both sensitivity and specificity to a desired level.",
    keywords = "14-3-3 protein, Biomarkers, Cerebrospinal fluid, Creutzfeldt-Jakob disease, β-amyloid, τ proteins",
    author = "Cseh, {Edina Katalin} and G. Veres and Krisztina Danics and Levente Szal{\'a}rdy and Nikolett N{\'a}n{\'a}si and P. Kliv{\'e}nyi and L. V{\'e}csei and D{\'e}nes Z{\'a}dori",
    year = "2019",
    month = "1",
    day = "30",
    doi = "10.18071/isz.72.0039",
    language = "English",
    volume = "72",
    pages = "39--47",
    journal = "Ideggyogyaszati Szemle",
    issn = "0019-1442",
    publisher = "Ifjusagi Lap-es Konyvkiado Vallalat",
    number = "1-2",

    }

    TY - JOUR

    T1 - Additional value of tau protein measurement in the diagnosis of Creutzfeldt-Jakob disease

    AU - Cseh, Edina Katalin

    AU - Veres, G.

    AU - Danics, Krisztina

    AU - Szalárdy, Levente

    AU - Nánási, Nikolett

    AU - Klivényi, P.

    AU - Vécsei, L.

    AU - Zádori, Dénes

    PY - 2019/1/30

    Y1 - 2019/1/30

    N2 - Since the definite diagnosis of Creutzfeldt-Jakob disease (CJD) can currently only be provided by autopsy, there is a special need for fine diagnostic tools in live patients to achieve accurate diagnosis as early as possible. The aim of this study was to perform a preliminary retrospective analysis on the utility of the measurement of total Tau (tTau) and some other biomarkers from the cerebrospinal fluid (CSF) of patients with rapidly progressive dementia in the diagnostic work up of CJD. Beside the assessment of relevant clinical data and the findings of electroencephalography and brain magnetic resonance imaging, the presence of 14-3-3 protein and the levels of tTau were determined by Western blot technique and enzyme-linked immunosorbent assay from the CSF of 19 patients diagnosed with rapidly progressive dementia between the period of 2004-2017 at the Department of Neurology, University of Szeged. This preliminary study provided 100% sensitivity for 14-3-3, and interestingly, only 40% specificity to support the clinical diagnosis of CJD. Regarding tTau, the sensitivity values were calculated to be 100% or 83%, whereas the specificity values were 71% or 86%, depending on the applied cut-off levels. The poor specificity of 14-3-3 is not in line with literature data and may be the result of the small number of patients in the cohort with non-prion disease, predominantly consisting of disorders with considerable tissue damage, whereas tTau presented good sensitivity and specificity values. The combined application of these and novel chemical biomarkers may increase both sensitivity and specificity to a desired level.

    AB - Since the definite diagnosis of Creutzfeldt-Jakob disease (CJD) can currently only be provided by autopsy, there is a special need for fine diagnostic tools in live patients to achieve accurate diagnosis as early as possible. The aim of this study was to perform a preliminary retrospective analysis on the utility of the measurement of total Tau (tTau) and some other biomarkers from the cerebrospinal fluid (CSF) of patients with rapidly progressive dementia in the diagnostic work up of CJD. Beside the assessment of relevant clinical data and the findings of electroencephalography and brain magnetic resonance imaging, the presence of 14-3-3 protein and the levels of tTau were determined by Western blot technique and enzyme-linked immunosorbent assay from the CSF of 19 patients diagnosed with rapidly progressive dementia between the period of 2004-2017 at the Department of Neurology, University of Szeged. This preliminary study provided 100% sensitivity for 14-3-3, and interestingly, only 40% specificity to support the clinical diagnosis of CJD. Regarding tTau, the sensitivity values were calculated to be 100% or 83%, whereas the specificity values were 71% or 86%, depending on the applied cut-off levels. The poor specificity of 14-3-3 is not in line with literature data and may be the result of the small number of patients in the cohort with non-prion disease, predominantly consisting of disorders with considerable tissue damage, whereas tTau presented good sensitivity and specificity values. The combined application of these and novel chemical biomarkers may increase both sensitivity and specificity to a desired level.

    KW - 14-3-3 protein

    KW - Biomarkers

    KW - Cerebrospinal fluid

    KW - Creutzfeldt-Jakob disease

    KW - β-amyloid

    KW - τ proteins

    UR - http://www.scopus.com/inward/record.url?scp=85061846355&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85061846355&partnerID=8YFLogxK

    U2 - 10.18071/isz.72.0039

    DO - 10.18071/isz.72.0039

    M3 - Article

    VL - 72

    SP - 39

    EP - 47

    JO - Ideggyogyaszati Szemle

    JF - Ideggyogyaszati Szemle

    SN - 0019-1442

    IS - 1-2

    ER -